Class-Action Suit Alleges Medtronic’s Rosy Forecast For MiniMed780G Misled Investors

14 Sep 2022

The lawsuit says that Medtronic continued to predict that the new insulin pump would be FDA-approved shortly, even as other regulatory issues and recalls in the diabetes division made that less likely.

Photo illustration of a black-and-white landscape with a portion tinted pink through rose-colored glasses. — • Source: Shutterstock

Medtronic plc misled shareholders about the future of the MiniMed 780G insulin pump, a class-action lawsuit recently filed in Minnesota federal court argues.

The suit, which was filed on 8 September, alleges that the medtech giant falsely told investors that the system was...